227 related articles for article (PubMed ID: 31291979)
1. Involvement of epigenetic modification of TERT promoter in response to all-trans retinoic acid in ovarian cancer cell lines.
Losi L; Lauriola A; Tazzioli E; Gozzi G; Scurani L; D'Arca D; Benhattar J
J Ovarian Res; 2019 Jul; 12(1):62. PubMed ID: 31291979
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumour effects of all-trans retinoid acid on serous ovarian cancer.
Lokman NA; Ho R; Gunasegaran K; Bonner WM; Oehler MK; Ricciardelli C
J Exp Clin Cancer Res; 2019 Jan; 38(1):10. PubMed ID: 30621740
[TBL] [Abstract][Full Text] [Related]
3. TERT promoter methylation and protein expression as predictive biomarkers for recurrence risk in patients with serous borderline ovarian tumours.
Losi L; Botticelli L; Garagnani L; Fabbiani L; Panini R; Gallo G; Sabbatini R; Maiorana A; Benhattar J
Pathology; 2021 Feb; 53(2):187-192. PubMed ID: 33032810
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic regulation of human telomerase reverse transcriptase promoter activity during cellular differentiation.
Liu L; Saldanha SN; Pate MS; Andrews LG; Tollefsbol TO
Genes Chromosomes Cancer; 2004 Sep; 41(1):26-37. PubMed ID: 15236314
[TBL] [Abstract][Full Text] [Related]
5. Acquired
Nesic K; Kondrashova O; Hurley RM; McGehee CD; Vandenberg CJ; Ho GY; Lieschke E; Dall G; Bound N; Shield-Artin K; Radke M; Musafer A; Chai ZQ; Ghamsari MRE; Harrell MI; Kee D; Olesen I; McNally O; Traficante N; Australian Ovarian Cancer Study ; DeFazio A; Bowtell DDL; Swisher EM; Weroha SJ; Nones K; Waddell N; Kaufmann SH; Dobrovic A; Wakefield MJ; Scott CL
Cancer Res; 2021 Sep; 81(18):4709-4722. PubMed ID: 34321239
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
7. [Relationship between human telomerase reverse transcriptase transcriptional level and telomerase activity in three ovarian cancer cell lines].
Song Y; Kong BH; Liu PS; Ma DX; Jiang S
Ai Zheng; 2003 May; 22(5):486-91. PubMed ID: 12753708
[TBL] [Abstract][Full Text] [Related]
8. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy.
Wu RC; Ayhan A; Maeda D; Kim KR; Clarke BA; Shaw P; Chui MH; Rosen B; Shih IeM; Wang TL
J Pathol; 2014 Mar; 232(4):473-81. PubMed ID: 24338723
[TBL] [Abstract][Full Text] [Related]
9. [In vitro treatment of ovarian cancer cells with cytosine deaminase-thymidine kinase fusion disuicide gene therapy system under the control of human telomerase reverse transcriptase gene promoter].
Kong BH; Song Y; Ma DX; Qu X; Jiang S
Zhonghua Fu Chan Ke Za Zhi; 2004 Jun; 39(6):390-5. PubMed ID: 15312323
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer.
Nicholson LJ; Smith PR; Hiller L; Szlosarek PW; Kimberley C; Sehouli J; Koensgen D; Mustea A; Schmid P; Crook T
Int J Cancer; 2009 Sep; 125(6):1454-63. PubMed ID: 19533750
[TBL] [Abstract][Full Text] [Related]
11. Complex context relationships between DNA methylation and accessibility, histone marks, and hTERT gene expression in acute promyelocytic leukemia cells: perspectives for all-trans retinoic acid in cancer therapy.
Garsuault D; Bouyer C; Nguyen E; Kandhari R; Prochazkova-Carlotti M; Chevret E; Forgez P; Ségal-Bendirdjian E
Mol Oncol; 2020 Jun; 14(6):1310-1326. PubMed ID: 32239597
[TBL] [Abstract][Full Text] [Related]
12. Development of high‑resolution melting analysis for ABCB1 promoter methylation: Clinical consequences in breast and ovarian carcinoma.
Vaclavikova R; Klajic J; Brynychova V; Elsnerova K; Alnaes GIG; Tost J; Kristensen VN; Rob L; Kodet R; Skapa P; Mrhalova M; Soucek P
Oncol Rep; 2019 Aug; 42(2):763-774. PubMed ID: 31173253
[TBL] [Abstract][Full Text] [Related]
13. Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer.
Lee PS; Teaberry VS; Bland AE; Huang Z; Whitaker RS; Baba T; Fujii S; Secord AA; Berchuck A; Murphy SK
Int J Cancer; 2010 Mar; 126(6):1378-89. PubMed ID: 19642140
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of ovarian cancer cell line Skov3 with HSV-tk/GCV under the control of human telomerase reverse transcriptase gene promoter].
Song Y; Kong BH; Liu PS; Ma DX; Qu X; Jiang S
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Aug; 25(4):438-42. PubMed ID: 12974091
[TBL] [Abstract][Full Text] [Related]
15. Molecular alterations in endometrial and ovarian clear cell carcinomas: clinical impacts of telomerase reverse transcriptase promoter mutation.
Huang HN; Chiang YC; Cheng WF; Chen CA; Lin MC; Kuo KT
Mod Pathol; 2015 Feb; 28(2):303-11. PubMed ID: 25081752
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of the cancer stem cell-related marker NANOG in ovarian serous carcinoma.
Lee M; Nam EJ; Kim SW; Kim S; Kim JH; Kim YT
Int J Gynecol Cancer; 2012 Nov; 22(9):1489-96. PubMed ID: 23095773
[TBL] [Abstract][Full Text] [Related]
17. Effect of all-trans retinoic acid on telomerase activity in ovarian cancer cells.
Purev E; Soprano DR; Soprano KJ
J Exp Clin Cancer Res; 2004 Jun; 23(2):309-16. PubMed ID: 15354417
[TBL] [Abstract][Full Text] [Related]
18. Insulin receptor substrate-1 is an important mediator of ovarian cancer cell growth suppression by all-trans retinoic acid.
Ravikumar S; Perez-Liz G; Del Vale L; Soprano DR; Soprano KJ
Cancer Res; 2007 Oct; 67(19):9266-75. PubMed ID: 17909034
[TBL] [Abstract][Full Text] [Related]
19. Common defects of different retinoic acid resistant promyelocytic leukemia cells are persistent telomerase activity and nuclear body disorganization.
Nason-Burchenal K; Maerz W; Albanell J; Allopenna J; Martin P; Moore MA; Dmitrovsky E
Differentiation; 1997 Aug; 61(5):321-31. PubMed ID: 9342843
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic priming of non-small cell lung cancer cell lines to the antiproliferative and differentiating effects of all-trans retinoic acid.
Greve G; Schiffmann I; Lübbert M
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2171-80. PubMed ID: 26008188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
